International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients

作者：Michael Charlton, Josh Levitsky, Bashar Aqel, John O’Grady, Julie Hemibach, Mary E. Rinella, John J. Fung, Marwan Ghabril, Ray Thomason, Patrizia Burra, Ester C. Little, Marina Berenguer, Abraham Shaked, James F. Trotter, John P. Roberts, Manuel I. Rodríguez-Dávalos, Mohamed Rela, Elizabeth A. Pomfret, Caroline Heyrend, Juan F. Gallegos‐Orozco, Faouzi Saliba · 发表于：Transplantation · 年份：2018 · DOI：10.1097/tp.0000000000002147 · 被引用次数：312 · 研究领域：Renal Transplantation Outcomes and Treatments、Organ Transplantation Techniques and Outcomes、Liver Disease and Transplantation

In Brief Effective immunosupression management is central to achieving optimal outcomes in liver transplant recipients. Current immunosuppression regimens and agents are highly effective in minimizing graft loss due to acute and chronic rejection but can also produce a substantial array of toxicities. The utilization of immunosuppression varies widely, contributing to the wide disparities in posttransplant outcomes reported between transplant centers. The International Liver Transplantation Society (ILTS) convened a consensus conference, comprised of a global panel of expert hepatologists, transplant surgeons, nephrologists, and pharmacologists to review the literature and experience pertaining to immunosuppression management to develop guidelines on key aspects of immunosuppression. The consensus findings and recommendations of the ILTS Consensus guidelines on immunosuppression in liver transplant recipients are presented in this article. The ILTS consensus document on immunosuppression in liver transplant recipients covers both the scope of therapeutic agents for induction and rejection therapy as well as an overview of complications and clinical management.